QUINTA-ANALYTICA
Martin Pavelka is a skilled professional in the pharmaceutical industry with extensive experience in quality assurance and quality control. Currently serving as a QAU Officer and Qualified Person at QUINTA-ANALYTICA since July 2023, Martin previously held several key roles at Glenmark Pharmaceuticals from January 2018 to June 2023, including QC Manager, Qualified Person, Responsible Person for Distribution, and QP Support. Additionally, Martin contributed to sterile manufacturing at Medites Pharma between July 2016 and December 2017. Academically, Martin holds a Master’s degree in Analytical Chemistry and a Bachelor’s degree in Bioorganic Chemistry from Palacký University in Olomouc.
This person is not in any offices
QUINTA-ANALYTICA
Quinta is a GCP/GLP/GMP-certified, EMA and FDA-inspected European CRO offering in-house clinical testing, pharmaceutical analysis, CMC and R&D. Quinta specializes in clinical studies, bioanalytics, method development and quality control for both small and large molecules, human and veterinary IMPs as well as generics. We provide unrivaled expertise to worldwide pharmaceutical and biotechnological clients across the entire pharma spectrum. Quinta is part of the Conscio group with headquarters in Munich, Germany, laboratories in Czechia, Austria, Slovakia, Germany and offices in the USA. Our main service areas include: 1) Clinical Testing: With 2 in-house clinical units providing BE/BA/PK studies, with capacity for 60+40 beds. 2) Bioanalytical Testing: GLP/GCP solutions for preclinical & clinical studies, small & large molecules, BE/BA/PK. 3) Research & Development: Analytical R&D, impurities, extractables & leachables, degradation, trace studies. 4) Pharmaceutical Quality Control: GMP quality control, batch testing, stabilities, HAPIs, inhalation, API sourcing. 5) Microbiology: GMP sterile & non-sterile testing, microbial/water analyses, endotoxins, antibiotics & vitamins. 6) Biopharmaceutical Quality Control: GLP/GMP bioanalysis, CMC, characterizations of peptide & protein IMPs, biosimilars. Quinta was founded in 1997 and has been successfully inspected by FDA more than 10 times. Quinta is headquartered in Prague, Czech Republic.